N. Lamfichekh

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.

C. Borg, C. Mariette, F. Fiteni, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer

C. Borg, F. Ghiringhelli, Thierry Nguyen, 2014, Cancer Chemotherapy and Pharmacology.

Human papillomaviruses in colorectal cancers: A case-control study in western patients.

M. Puyraveau, Z. Lakkis, L. Vuitton, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma

C. Borg, C. Mariette, F. Fiteni, 2016, Cancer medicine.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

[Surgical treatment of Verneuil's disease (hidradenitis suppurativa): 15 cases].

P. Humbert, G. Mantion, C. Runser, 2001, Annales de dermatologie et de venereologie.

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels

C. Borg, Thierry Nguyen, Stefano Kim, 2013, BMC Cancer.